Related Experiment Videos
Lanreotide and beyond: extending the therapeutic horizons
Hospital Medicine (London, England : 1998)
|February 3, 2000
Summary
Somatostatin, a hormone that inhibits growth, shows promise for treating diabetes and cancer. Targeting its five receptor subtypes enhances treatment efficacy and minimizes side effects.
Area of Science:
- Endocrinology
- Pharmacology
- Oncology
Background:
- Somatostatin's growth hormone inhibiting effects were discovered 30 years ago.
- Understanding of somatostatin's diverse activities has significantly advanced.
- Potential therapeutic applications are emerging for various disorders.
Purpose of the Study:
- To explore the therapeutic potential of somatostatin.
- To leverage the understanding of somatostatin receptor subtypes for targeted treatments.
- To maximize treatment efficacy while minimizing adverse effects.
Main Methods:
- Identification and characterization of five somatostatin receptor subtypes.
- Development of targeted therapeutic strategies based on receptor knowledge.
Main Results:
- A deeper understanding of somatostatin's biological activities.
- The ability to precisely target somatostatin receptor subtypes.
- Potential for improved treatment outcomes in diabetes and cancer.
Conclusions:
- Targeted therapies based on somatostatin receptor subtypes offer a promising approach.
- Somatostatin-based treatments have the potential to revolutionize management of endocrine disorders, cancers, and other diseases.
- Further research into somatostatin and its receptors is warranted.